Illustration: Tiffany Herring/Axios
Odyssey Therapeutics, an autoimmune and inflammation drug developer, raised $304 million in an upsized IPO at $18 per share.
Why it matters: The company joins a growing group of biotech companies debuting this spring — most of which have priced at the top of their ranges.
